Sujay Srinivas

708 total citations
36 papers, 251 citations indexed

About

Sujay Srinivas is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Sujay Srinivas has authored 36 papers receiving a total of 251 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 15 papers in Surgery. Recurrent topics in Sujay Srinivas's work include Pancreatic and Hepatic Oncology Research (9 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (6 papers) and Neuroendocrine Tumor Research Advances (5 papers). Sujay Srinivas is often cited by papers focused on Pancreatic and Hepatic Oncology Research (9 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (6 papers) and Neuroendocrine Tumor Research Advances (5 papers). Sujay Srinivas collaborates with scholars based in India. Sujay Srinivas's co-authors include Prabhat Bhargava, Anant Ramaswamy, Vikas Ostwal, Nandini Menon, Sudeep Gupta, Jyoti Bajpai, Vikas Ostwal, Akhil Kapoor, Shailesh V. Shrikhande and Kumar Prabhash and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Sujay Srinivas

34 papers receiving 239 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sujay Srinivas India 9 122 80 58 45 27 36 251
Jeffrey T. Yorio United States 8 193 1.6× 136 1.7× 70 1.2× 34 0.8× 30 1.1× 22 323
Syed Hammad Tirmazy United Arab Emirates 5 125 1.0× 74 0.9× 54 0.9× 23 0.5× 27 1.0× 16 237
Rawad Elias United States 10 389 3.2× 159 2.0× 48 0.8× 51 1.1× 42 1.6× 28 535
Giuseppina Arcangeli Italy 7 227 1.9× 101 1.3× 69 1.2× 24 0.5× 35 1.3× 11 336
Capucine Baldini France 10 184 1.5× 96 1.2× 46 0.8× 24 0.5× 36 1.3× 19 336
Melissa A.L. Vyfhuis United States 10 182 1.5× 201 2.5× 35 0.6× 24 0.5× 28 1.0× 30 390
Ceri Powell United Kingdom 11 119 1.0× 106 1.3× 108 1.9× 21 0.5× 16 0.6× 23 349
Boris Hristov United States 7 79 0.6× 162 2.0× 86 1.5× 21 0.5× 12 0.4× 14 256
Anuradha Thiagarajan Singapore 9 92 0.8× 96 1.2× 66 1.1× 19 0.4× 15 0.6× 21 267
Gregory Rosenblatt United States 9 73 0.6× 97 1.2× 100 1.7× 12 0.3× 56 2.1× 25 311

Countries citing papers authored by Sujay Srinivas

Since Specialization
Citations

This map shows the geographic impact of Sujay Srinivas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sujay Srinivas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sujay Srinivas more than expected).

Fields of papers citing papers by Sujay Srinivas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sujay Srinivas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sujay Srinivas. The network helps show where Sujay Srinivas may publish in the future.

Co-authorship network of co-authors of Sujay Srinivas

This figure shows the co-authorship network connecting the top 25 collaborators of Sujay Srinivas. A scholar is included among the top collaborators of Sujay Srinivas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sujay Srinivas. Sujay Srinivas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Bhargava, Prabhat, Vikas Ostwal, Sujay Srinivas, et al.. (2023). Gemcitabine, cisplatin, nab-paclitaxel: The effectiveness of this regimen for gall bladder cancer.. Journal of Clinical Oncology. 41(16_suppl). e16168–e16168.
3.
Ramaswamy, Anant, et al.. (2023). Modified FOLFIRINOX compared to Gemcitabine & nab-Paclitaxel in advanced pancreatic ductal adenocarcinoma - results of a match-pair analysis. The Indian Journal of Medical Research. 157(1). 57–65. 4 indexed citations
4.
Kapoor, Akhil, et al.. (2022). Neoadjuvant chemotherapy in technically unresectable head and neck cancers: a retrospective audit. ecancermedicalscience. 16. 1460–1460. 4 indexed citations
5.
Chandrasekharan, Arun, Prabhat Bhargava, Sujay Srinivas, et al.. (2022). Outcomes of Ewing sarcoma in adults over 40 years of age from a low-middle income country. ecancermedicalscience. 16. 1361–1361. 4 indexed citations
6.
Patil, Vijay, Vanita Noronha, Nandini Menon, et al.. (2022). Phase 3 randomized study comparing docetaxel-platinum with docetaxel-platinum-5 fluorouracil as neoadjuvant chemotherapy in technically unresectable oral cancer.. Journal of Clinical Oncology. 40(16_suppl). 6013–6013. 3 indexed citations
7.
Ramaswamy, Anant, Sujay Srinivas, Vikram Chaudhari, et al.. (2022). Systemic therapy in pancreatic ductal adenocarcinomas (PDACs)—basis and current status. ecancermedicalscience. 16. 1367–1367. 4 indexed citations
8.
Ramaswamy, Anant, Prabhat Bhargava, Sujay Srinivas, et al.. (2022). Perioperative Modified FLOT Versus EOX in Locally Advanced Resectable Gastric and Gastro-Oesophageal Junction Adenocarcinoma: Results of a Matched-Pair Analysis. Journal of Gastrointestinal Cancer. 54(3). 820–828. 3 indexed citations
9.
Bhargava, Prabhat, Vikas Ostwal, Sujay Srinivas, et al.. (2022). An Analysis of Tolerance and Early Survival Outcomes with Perioperative Modified FLOT in Gastric Cancers. SHILAP Revista de lepidopterología. 11(2). 112–117. 4 indexed citations
10.
11.
Srinivas, Sujay, Vikas Ostwal, Prabhat Bhargava, et al.. (2022). Modified FOLFIRINOX (mFOLFIRINOX) in high risk locally advanced rectal adenocarcinomas.. Journal of Clinical Oncology. 40(4_suppl). 108–108. 1 indexed citations
12.
Srinivas, Sujay & Jyoti Bajpai. (2021). Immunotherapy in Special and Rare Situations: A Brief Review. SHILAP Revista de lepidopterología. 4(4). 180–184. 3 indexed citations
13.
Ostwal, Vikas, Anant Ramaswamy, Prabhat Bhargava, et al.. (2021). Cancer Aging Research Group (CARG) score in older adults undergoing curative intent chemotherapy: a prospective cohort study. BMJ Open. 11(6). e047376–e047376. 26 indexed citations
14.
Singh, Gunjesh Kumar, Hollis Dsouza, Nandini Menon, et al.. (2021). Safety and efficacy of bevacizumab biosimilar in recurrent/ progressive glioblastoma. ecancermedicalscience. 15. 1166–1166. 6 indexed citations
15.
Bajpai, Jyoti, Arun Chandrasekharan, Prabhat Bhargava, et al.. (2021). Adolescent–adult nonmetastatic Ewing sarcoma—Experience from a large developing country. Pediatric Blood & Cancer. 68(9). e29081–e29081. 6 indexed citations
16.
Noronha, Vanita, George Abraham, Vijay Patil, et al.. (2021). A real‐world data of Immune checkpoint inhibitors in solid tumors from India. Cancer Medicine. 10(5). 1525–1534. 23 indexed citations
17.
Ostwal, Vikas, Sandip Basu, Prabhat Bhargava, et al.. (2020). Capecitabine-Temozolomide in Advanced Grade 2 and Grade 3 Neuroendocrine Neoplasms: Benefits of Chemotherapy in Neuroendocrine Neoplasms with Significant <sup>18</sup>FDG Uptake. Neuroendocrinology. 111(10). 998–1004. 16 indexed citations
18.
Kapoor, Akhil, Ashutosh Jain, Prabhat Bhargava, et al.. (2020). Chemotherapy-Induced Nausea and Vomiting in Gastrointestinal Cancer Patients: Do We Need to Revisit Guidelines?. South Asian Journal of Cancer. 9(4). 245–249. 1 indexed citations
19.
Ostwal, Vikas, Anant Ramaswamy, Alok Goel, et al.. (2018). Outcomes with second-line chemotherapy in advanced pancreatic cancers: A retrospective study from a tertiary cancer center in India. Indian Journal of Cancer. 55(2). 144–144. 2 indexed citations
20.
Ostwal, Vikas, Anant Ramaswamy, Alok Goel, et al.. (2018). Treatment practices for metastatic pancreatic cancer: Can we deliver an appropriately efficacious and safe regimen in Indian patients?. Indian Journal of Cancer. 55(2). 138–138. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jeffrey T. Yorio Breakdown of academic impact, for papers by Syed Hammad Tirmazy Breakdown of academic impact, for papers by Rawad Elias Breakdown of academic impact, for papers by Giuseppina Arcangeli Breakdown of academic impact, for papers by Capucine Baldini Breakdown of academic impact, for papers by Melissa A.L. Vyfhuis Breakdown of academic impact, for papers by Ceri Powell Breakdown of academic impact, for papers by Boris Hristov Breakdown of academic impact, for papers by Anuradha Thiagarajan Breakdown of academic impact, for papers by Gregory Rosenblatt
Rankless by CCL
2026